|
||||||
|
|
|
|
|
|
|
| John L Marshall, MD Chief, Hematology and Oncology Director of Developmental Therapeutics and GI Oncology Lombardi Comprehensive Cancer Center Georgetown University Washington, DC Lawrence D Wagman, MD Chair, Division of Surgery Director, Department of General Oncology Surgery Section Head, Hepatobiliary Section City of Hope National Medical Center Duarte, California |
Robert A Wolff, MD Associate Professor of Medicine Deputy Chairman for Clinical Affairs Department of Gastrointestinal Medical Oncology The University of Texas MD Anderson Cancer Center Houston, Texas W Douglas Wong, MD Chief, Colorectal Service Stuart H Q Quan Chair in Colorectal Surgery Memorial Sloan-Kettering Cancer Center New York, New York |
CONTENT VALIDATION AND DISCLOSURES
Research To Practice is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved by a peer review content validation process. The content of each activity is reviewed by both a member of the scientific staff and an external independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
The scientific staff and consultants for Research To Practice are involved in the development and review of content for educational activities and report the following real or apparent conflicts of interest for themselves (or their spouses/partners) that have been resolved through a peer review process: Richard Kaderman, PhD, Neil Love, MD, Douglas Paley, Michelle Paley, MD, Margaret Peng, Lilliam Sklaver Poltorack, PharmD, Chris Thomson, MD, MS and Kathryn Ault Ziel, PhD — no real or apparent conflicts of interest to report; Sally Bogert, RNC, WHCNP — shareholder of Amgen Inc. Research To Practice receives education grants from Abraxis Oncology, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, Biogen Idec, Genentech BioOncology, Genomic Health Inc, Roche Laboratories Inc and Sanofi-Aventis, who have no influence on the content development of our educational activities.
In addition, the following faculty (and their spouses/partners) have reported real or apparent conflicts of interest that have been resolved through a peer review process:
Dr Marshall — Consulting Fees, Speakers Bureau and Contracted Research: Genentech BioOncology, Pfizer Inc, Roche Laboratories Inc, Sanofi-Aventis. Dr Wagman — No financial interests or affiliations to disclose. Dr Wolff — Consulting Fees: Eli Lilly and Company, Pfizer Inc. Dr Wong — Consulting Fees: B-K Medical.
This educational activity contains discussion of published and/or investigational uses of agents that are
not indicated by the Food and Drug Administration. Research To Practice does not recommend the use
of any agent outside of the labeled indications. Please refer to the official prescribing information for each
product for discussion of approved indications, contraindications and warnings. The opinions expressed
are those of the presenters and are not to be construed as those of the publisher or grantors.
